Healthcare -
Biotechnology - NASDAQ - US
$ 0.389
-2.77 %
$ 483 K
Market Cap
-0.01
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Virpax Pharmaceuticals, Inc.
| Current Assets | 1.56 B |
| Cash & Short-Term Investments | 1.51 B |
| Receivables | 0 |
| Other Current Assets | 42.6 M |
| Non-Current Assets | 0 |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 2.47 B |
| Accounts Payable | 0 |
| Short-Term Debt | 0 |
| Other Current Liabilities | 2.47 B |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Virpax Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 12.1 B |
| Operating Income | -12.1 B |
| Other Expenses | -12.1 B |
| Net Income | -12.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Virpax Pharmaceuticals, Inc.
| Net Income | -12.1 M |
| Depreciation & Amortization | 91 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 135 M |
| Change in Working Capital | -4.78 M |
| Others | -16.8 B |
| Free Cash Flow | -16.7 B |
Wall Street Analysts Price Targets
Virpax Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for VRPX of $3 , with forecasts ranging from
a
low of
$3 to a high of $3 .
VRPX Lowest Price Target
Wall Street Target
3 USD
671.21%
VRPX Average Price Target
Wall Street Target
3 USD
671.21%
VRPX Highest Price Target
Wall Street Target
3 USD
671.21%
4. DIVIDEND
ANALYSIS
VRPX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Virpax Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Virpax Pharmaceuticals Announces Reverse Stock Split
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on.
businesswire.com
- 3 months ago
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
BERWYN, Penn.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding (“DRF”) study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediat.
businesswire.com
- 3 months ago
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look t.
businesswire.com
- 4 months ago
Virpax's NES100 to be Presented at The Society of Toxicology by NCATS
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its NES100 dose range finding toxicity study will be presented at The Society of Toxicology (SOT) 64th annual meeting and Tox Expo taking place March 16-20th in Orlando, FL. This is a p.
businesswire.com
- 4 months ago
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
On Friday, Virpax Pharmaceuticals, Inc. VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).
benzinga.com
- 4 months ago
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its senior director of portfolio management, Matthew Barnes, will be presenting at Outsourcing in Clinical Trial Conference. The Outsourcing in Clinical Trials (OCT) is a leading confer.
businesswire.com
- 5 months ago
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering
NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) in the successful close of its $6 million follow-on offering.
globenewswire.com
- 5 months ago
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $6.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.20 per share (minus $0.00001 per pr.
businesswire.com
- 5 months ago
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding (“DRF”) study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate.
businesswire.com
- 7 months ago
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the c.
businesswire.com
- 7 months ago
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (Nasdaq: VRPX) successful $5.0 million public offering of common stock and pre-funded warrants.
globenewswire.com
- 7 months ago
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pr.
businesswire.com
- 7 months ago
8. Profile
Summary
Virpax Pharmaceuticals, Inc. VRPX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 483 K
Dividend Yield
0.00%
Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Contact
1055 Westlakes Drive, Berwyn, PA, 19312
https://www.virpaxpharma.com
IPO
Date
Feb. 17, 2021
Employees
2
Officers
Mr. Jatinder Dhaliwal
Chief Executive Officer & Chairman
Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.
Chief Scientific Officer